Exploring Anticancer Activities and Structure-Activity Relationships of Binuclear Oxidovanadium(IV) Complexes

Area of Science:

• Coordination Chemistry
• Medicinal Chemistry
• Biochemistry

Background:

• Dimeric mixed-ligand oxidovanadium complexes with symmetric and asymmetric structures were synthesized.
• Previous studies reported asymmetric binuclear complexes, motivating the investigation of symmetric analogues.
• Density functional theory suggested potential reactivity with biomolecules for anticancer applications.

Purpose of the Study:

• To synthesize and fully characterize novel dimeric mixed-ligand oxidovanadium complexes.
• To investigate the structural stability and anticancer activities of these complexes.
• To explore structure-activity relationships and mechanisms of action against cancer cells.

Main Methods:

• Synthesis and characterization of dimeric oxidovanadium complexes using analytical techniques.
• In vitro antitumor activity screening using MTT assays on HepG2 and SMMC-7721 hepatocellular carcinoma cell lines.
• DNA binding affinity studies (Kb) and cleavage assays, flow cytometry for apoptosis and cell cycle analysis.

Main Results:

• Complex 2 ([V2O2(1,3-pdta)(phen)2]·6H2O) exhibited the highest inhibitory potency against HepG2 and SMMC-7721 cells (IC50 values of 2.07 ± 0.72 μM and 13.00 ± 3.06 μM, respectively).
• Complex 2 demonstrated stronger binding affinity to calf thymus DNA (Kb = 5.71 × 10^4 M^-1) and superior DNA cleavage activity compared to complexes 1 and 3.
• Mechanistic studies revealed that complex 2 blocks DNA synthesis and cell division, inducing apoptosis in cancer cells.

Conclusions:

• Dimeric oxidovanadium complexes, particularly complex 2, show significant promise as effective and safe anticancer agents.
• The symmetric binuclear structure and DNA interaction capabilities contribute to the observed antitumor effects.
• Further development of these vanadium complexes could lead to novel therapeutic strategies for hepatocellular carcinoma.